Table 3.

Characteristics of immunocompromised patients.

Patients	Age (y)	Gender	Origin of immunodepression	Other comorbidities	FiO2 at the time of BAL	Micorbiological results	Final diagnosis
1	53	M	Glucocorticoids	RA-ILD	28	—	RA-ILD exacerbation
2	61	F	Liver transplant	CKI, HT	21	Haemophilus influenzae	Haemophilus influenzae pneumonia
3	63	M	Kidney transplant	CKI, HT, cardiac failure	30	Pneumocystis jirovecii	Pneumocystis jirovecii infection
4	20	M	Heart transplant	Cardiac failure	21	Influenza A	Influenza A infection
5	35	M	Glucocorticoids	Ulcerative colitis	21	—	COP
6	53	F	Glucocorticoids	Acute alcoholic hepatitis, liver failure	80	Influenza A	Influenza A infection
7	68	F	Glucocorticoids	Sarcoidosis, HT, diabetes	35	SARS-CoV-2	SARS-CoV-2 infection
8	71	M	Kidney transplant	HT, multiple myeloma	24	Metapneumovirus	Metapneumovirus infection
9	48	M	Untreated HIV	HT	27	—	Undetermined
10	81	M	Chemotherapy	CML, CKI	30	—	Undetermined
11	41	F	Combination of immunosuppresive agents	Ankylosing spondylitis	25	Chlamydia pneumoniae	Chlamydia pneumoniae infection
12	74	F	Heart transplant	CKI, HT, diabetes	21	SARS-CoV-2	SARS-CoV-2 infection
13	58	F	Glucocorticoids	Severe asthma	24	Aspergillus fumigatus	Invasive aspergillosis
14	38	F	Glucocorticoids	Acute alcoholic hepatitis, liver failure	21	—	Hepatopulmonary syndrome
15	71	M	Chemotherapy	CLL, CKI	30	Herpes simplex virus	Herpes simplex virus infection
16	71	M	Liver transplant	HT, AF	35	—	Cardiogenic pulmonary edema
17	64	M	Sarcoidosis	Emphysema	50	—	Sarcoidosis exacerbation

Abbreviations: M—male; F—female; HIV—human immunodeficiency virus; RA-ILD—rheumatoid arthritis-associated interstitial lung disease; CKI—chronic kidney injury; HT—hypertension; CML—chronic myeloid leukemia; COP—cryptogenic organizing pneumonia; CLL—chronic lymphoid leukemia; AF—atrial fibrillation.